We did not control for other factors known to impact response to intravesical therapy such as presence of high-risk mutations (p53 loss or mutation) (Knowles and Hurst, 2015), so it is also possible these findings may be associated with tumor biology alone. This evidence concerns the gene TP53 and neoplasm.